[Treatment for symptoms of pseudoaldosteronism].
Shibata
Hirotaka
H
Ito
Hiroshi
H
D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000037:antagonists & inhibitors; D000450:Aldosterone / Q000378:metabolism; D004039:Diet, Sodium-Restricted; D006035:Glycyrrhiza / Q000009:adverse effects; D019695:Glycyrrhizic Acid / Q000009:adverse effects*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D007685:Kidney Tubules, Collecting / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011188:Potassium / Q000008:administration & dosage* / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use*
D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000450:Aldosterone; D019695:Glycyrrhizic Acid; D012964:Sodium; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; D011188:Potassium; D006854:Hydrocortisone